問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

王全正

Recruiting

List

61Cases

2022-11-18 - 2027-12-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2025-03-31 - 2028-01-31

Phase I

Active
A Phase 1B, Multicenter, Open-Label Study of the Safety and Efficacy of CHS-114 in Combination With Toripalimab With or Without Other Treatments in Participants With Advanced or Metastatic Solid Tumors

  • Condition/Disease

    Metastatic Solid Tumor、 Advanced Solid Tumor

  • Test Drug

    靜脈點滴注射劑 靜脈點滴注射劑

Participate Sites
10Sites

Recruiting10Sites

2024-06-28 - 2028-03-31

Phase III

Active
A Phase 3 Open-label, Randomized Controlled Study to Evaluate the Efficacy and Safety of Petosemtamab Compared With Investigator's Choice Monotherapy Treatment in Previously Treated Patients With Incurable, Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma

  • Condition/Disease

    Head and Neck Squamous Cell Carcinoma

  • Test Drug

    Intravenous infusion

Participate Sites
8Sites

Recruiting8Sites

2024-06-28 - 2028-05-31

Phase III

Active
A phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma

  • Condition/Disease

    Head and Neck Squamous Cell Carcinoma

  • Test Drug

    petosemtamab

Participate Sites
7Sites

Recruiting7Sites

2019-02-01 - 2026-11-30

Phase III

Active
xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
8Sites

Recruiting8Sites

2023-01-02 - 2029-06-01

Phase III

Active
Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Mocravimod as Adjunctive and Maintenance Treatment in Adult AML Patients Undergoing Allogeneic HCT

  • Condition/Disease

    Adult Acute Myeloid Leukemia

  • Test Drug

    mocravimod

Participate Sites
4Sites

Recruiting4Sites

2021-03-15 - 2025-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2025-03-01 - 2029-12-31

Others

Active
A Double-Blind, Randomized, Active-Controlled, Parallel-group, Phase 1/3 Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma

  • Condition/Disease

    Refractory or Relapsed Multiple Myeloma

  • Test Drug

    皮下注射劑

Participate Sites
6Sites

Recruiting6Sites

2024-01-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-01-01 - 2027-11-14

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

1 2 3 4 5 7
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB